Amicus Therapeutics Inc Quick Ratio (FOLD) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Amicus Therapeutics inc   (NASDAQ: FOLD)

Amicus Therapeutics Inc 's Quick Ratio

FOLD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 1.23 a new company low.

Within Major Pharmaceutical Preparations industry 328 other companies have achieved higher Quick Ratio than Amicus Therapeutics Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 1240 to 1622.

Explain Quick Ratio?
How much Cash & cash equivalents FOLD´s has?
What are FOLD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FOLD Quick Ratio (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 59.94 % 25.8 % -0.25 % 7.59 % -13.83 %
Y / Y Cash & cash equivalent Change 17.44 % 5.64 % -11.18 % 4.58 % -12.67 %
Quick Ratio MRQ 1.23 1.33 1.38 1.64 1.68
FOLD's Total Ranking # 1622 # 1240 # 890 # 1192 # 814
Seq. Current Liabilities Change 19.55 % 18.66 % 9.65 % 2.82 % -5.97 %
Seq. Cash & cash equivalent Change 11.25 % 14.22 % -7.81 % 0.25 % 0.08 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 329
Healthcare Sector # 589
Overall Market # 1622


Quick Ratio Statistics
High Average Low
21.38 4.83 1.23
(Jun 30 2015)   (Dec 31 2025)




Financial Statements
Amicus Therapeutics Inc 's Current Liabilities $ 238 Millions Visit FOLD's Balance sheet
Amicus Therapeutics Inc 's Cash & cash equivalent $ 294 Millions Visit FOLD's Balance sheet
Source of FOLD's Sales Visit FOLD's Sales by Geography


Cumulative Amicus Therapeutics Inc 's Quick Ratio

FOLD's Quick Ratio for the trailling 12 Months

FOLD Quick Ratio

 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 22.74 % 4.26 % -3.81 % -2.42 % -3.54 %
Y / Y Cash & cash equivalent TTM Growth 3.96 % -3.89 % -7.96 % -5.73 % -9.09 %
Quick Ratio TTM 1.37 1.49 1.56 1.61 1.62
Total Ranking TTM # 2472 # 2879 # 2681 # 2887 # 1036
Seq. Current Liabilities TTM Growth 13.34 % 6.5 % -0.07 % 1.75 % -3.73 %
Seq. Cash & cash equivalent TTM Growth 4.38 % 1.44 % -2.88 % 1.1 % -3.5 %

Quick ratio ranking by company, industry and sector >> Back to FOLD Financial Strength Comparisons >> Go to Compare FOLD Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q4 2025 to $237.83 millions, cumulative Quick Ratio decreased to 1.37 below the Amicus Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 281 other companies have achieved higher Quick Ratio than Amicus Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2472, from total ranking during the twelve months ending third quarter 2025 at 2879.

Explain Quick Ratio?
How much Cash & cash equivalents FOLD´s has?
What are FOLD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 282
Healthcare Sector # 597
Within the Market # 2472


trailing twelve months Quick Ratio Statistics
High Average Low
10.39 3.78 1.37
(June 30. 2015)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Alumis inc   3.38 $ 308.501  Millions$ 91.143  Millions
Quoin Pharmaceuticals Ltd   3.38 $ 18.745  Millions$ 5.547  Millions
Rhythm Pharmaceuticals Inc   3.38 $ 388.949  Millions$ 115.197  Millions
Urogen Pharma Ltd   3.32 $ 160.074  Millions$ 48.225  Millions
Decoy Therapeutics Inc   3.29 $ 13.710  Millions$ 4.166  Millions
Bolt Biotherapeutics Inc   3.26 $ 27.505  Millions$ 8.435  Millions
Bullfrog Ai Holdings Inc   3.25 $ 2.184  Millions$ 0.672  Millions
Madrigal Pharmaceuticals Inc   3.18 $ 983.559  Millions$ 309.270  Millions
Aclaris Therapeutics Inc   3.17 $ 90.751  Millions$ 28.645  Millions
Pyxis Oncology Inc   3.16 $ 66.857  Millions$ 21.131  Millions
Skye Bioscience Inc   3.14 $ 25.737  Millions$ 8.206  Millions
Acurx Pharmaceuticals inc   3.12 $ 7.556  Millions$ 2.421  Millions
Gri Bio Inc   3.11 $ 8.229  Millions$ 2.643  Millions
Cypherpunk Technologies Inc   3.11 $ 14.035  Millions$ 4.520  Millions
Inhibitor Therapeutics Inc   3.10 $ 2.375  Millions$ 0.766  Millions
Kyntra Bio Inc   3.04 $ 88.978  Millions$ 29.242  Millions
Tao Synergies Inc   3.03 $ 5.498  Millions$ 1.814  Millions
Kala Bio inc   3.03 $ 7.557  Millions$ 2.494  Millions
Lb Pharmaceuticals Inc  3.01 $ 30.466  Millions$ 10.126  Millions
Ardelyx inc   2.99 $ 264.689  Millions$ 88.605  Millions
Kiniksa Pharmaceuticals International Plc  2.98 $ 414.074  Millions$ 139.184  Millions
Gt Biopharma Inc   2.95 $ 6.811  Millions$ 2.308  Millions
Cytomx Therapeutics Inc   2.94 $ 137.052  Millions$ 46.615  Millions
Mirum Pharmaceuticals Inc   2.89 $ 732.452  Millions$ 253.075  Millions
Nurix Therapeutics Inc   2.86 $ 246.960  Millions$ 86.471  Millions
Proqr Therapeutics N v   2.85 $ 103.503  Millions$ 36.334  Millions
Cellectar Biosciences Inc   2.84 $ 13.196  Millions$ 4.650  Millions
Verastem Inc   2.84 $ 204.990  Millions$ 72.268  Millions
Pds Biotechnology Corp  2.83 $ 26.712  Millions$ 9.447  Millions
Tvardi Therapeutics Inc   2.82 $ 30.811  Millions$ 10.926  Millions

Date modified: 2026-06-22T14:32:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.